Citations

Clear

554 citation(s) found for "Li, Gerald".

International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)
O’Mahony, Constantinos , Jichi, Fatima, Ommen, Steve R. , Christiaans, Imke , Arbustini, Eloisa , García‐Pavía, Pablo , Olivotto, Iacopo , Kitaoka, Hiroaki , Gotsman, Israel , Carr‐White, Gerald, Mogensen, Jens , Antoniades, Loizos , Tang, Hak Chiaw , Geske, Jeffrey B. , Siontis, Konstantinos C. , Mahmoud, Karim D. , Vermeer, Alexa M.C. , Wilde, Arthur A.M. , Favalli, Valentina , Guttmann, Oliver , Gallego‐Delgado, María , Domínguez, Fernándo , Tanini, Ilaria , Kubo, Toru , Keren, Andre , Bueser, Teofila , Waters, Sarah, Issa, Issa Farah , Malcolmson, James , Burns, Tom, Sekhri, Neha, Hoeger, Christopher W. , Omar, Rumana , Elliott, Perry , Olivotto, Iacopo , Garcia-Pavia, Pablo , Geske, Jeffrey B , Cecchi, Franco , Mohiddin, Saidi , Maurer, Matthew J. , Dominguez, Fernando

Mayo Clinic

Circulation | November 30, 2017 | Volume: 137 | Issue: 10 | Pages: 1015-1023

10.1161/circulationaha.117.030437 | PMID 29191938 Get It

Background: Identification of people with hypertrophic cardiomyopathy (HCM) who are at risk of sudden cardiac death (SCD) and require a prophylactic implantable cardioverter defibrillator is challenging. In 2014, the European Society of Cardiology proposed a new risk stratification method based on a risk prediction model (HCM Risk-SCD) that estimates the 5-year risk of SCD. The aim was to externally validate the 2014 European Society of Cardiology recommendations in a geographically diverse cohort of patients recruited from the United States, Europe, the Middle East, and Asia. Methods: This was an observational, retrospective, longitudinal cohort study. Results: The cohort consisted of 3703 patients. Seventy three (2%) patients reached the SCD end point within 5 years of follow-up (5-year incidence, 2.4% [95% confidence interval {CI}, 1.9–3.0]). The validation study revealed a calibration slope of 1.02 (95% CI, 0.93–1.12), C-index of 0.70 (95% CI, 0.68–0.72), and D-statistic of 1.17 (95% CI, 1.05–1.29). In a complete case analysis (n= 2147; 44 SCD end points at 5 years), patients with a predicted 5-year risk of <4% (n=1524; 71%) had an observed 5-year SCD incidence of 1.4% (95% CI, 0.8–2.2); patients with a predicted risk of ≥6% (n=297; 14%) had an observed SCD incidence of 8.9% (95% CI, 5.96–13.1) at 5 years. For every 13 (297/23) implantable cardioverter defibrillator implantations in patients with an estimated 5-year SCD risk ≥6%, 1 patient can potentially be saved from SCD. Conclusions: This study confirms that the HCM Risk-SCD model provides accurate prognostic information that can be used to target implantable cardioverter defibrillator therapy in patients at the highest risk of SCD.
CRRL269: a novel designer and renal-enhancing pGC-A peptide activator
Chen, Yang, Harty, Gail J., Huntley, Brenda K., Heublein, Denise M., Harders, Gerald E., Meems, Laura M.G., Pan, Shuchong, Sangaralingham, S. Jeson , Ichiki, Tomoko , Burnett, John C. , Iyer, Seethalakshmi R., Meems, Laura, Chen, Yang, Iyer, Seethalakshmi , Sangaralingham, S. Jeson

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | November 29, 2017 | Volume: 314 | Issue: 3 | Pages: R407-R414

10.1152/ajpregu.00286.2017 | PMID 29187381 Get It

The natriuretic peptides (NPs) B-type NP (BNP) and urodilatin (URO) exert renal protective properties via the particulate guanylyl cyclase A receptor (pGC-A). As a potential renal-enhancing strategy, we engineered a novel designer peptide that we call CRRL269. CRRL269 was investigated in human cell lines and in normal canines to define potential cardiorenal enhancing actions. The mechanism of its cardiorenal selective properties was also investigated. In vitro NP receptor activity was quantified with guanosine 3′,5′-cyclic monophosphate generation. In vivo effects were determined in normal canine acute infusion studies. We observed that CRRL269 demonstrated enhanced pGC-A activity in renal compared with nonrenal cell lines. CRRL269 exerted enhanced resistance to neprilysin compared with URO. Importantly, CRRL269 exhibited significant and greater increases in urinary sodium excretion and diuresis, with less blood pressure reduction, than BNP or URO in normal canines. CRRL269 retained potent renin-angiotensin-aldosterone system (RAAS) suppressing properties shared by URO and BNP. Also, CRRL269 exerted less arterial relaxation and higher cAMP cardiomyocytes generation than BNP. CRRL269 possessed superior renal and pGC-A activating properties compared with BNP or URO in vitro. CRRL269 exerted enhanced renal actions while suppressing RAAS in vivo and with less hypotension compared with URO or BNP. Together, our study suggests that CRRL269 is a promising innovative renal-enhancing drug, with favorable protective actions targeting cardiorenal disease states through the pGC-A receptor.
Association of anxiety and depression concerns with overall levels of patient reported distress during radiotherapy.
Landy, Robin, Whitaker, D., Jagadesh, Niveditha , Strong, Gerald, Chimato, Nicolette T., Kaleem, Tasneem , Buskirk, Steven J., Vallow, Laura A., Tzou, Katherine S., Peterson, Jennifer , Day, Atiya, Nelson, Kimberly, Habboush, Jacob, May, Byron C. , Heckman, Michael G. , Ko, Stephen J. , Miller, Robert C.

Mayo Clinic

Journal of Clinical Oncology | November 14, 2017 | Volume: 35 | Issue: 31_suppl | Pages: 182-182

10.1200/jco.2017.35.31_suppl.182 Get It

182 Background: The purpose of this study was to examine the associations of three different measures of anxiety and depression with patient reported distress (PRD) level and survival after radiotherapy (RT). Methods: 518 patients who underwent RT between 2012 and 2016 were included in this retrospective study. PRD was assessed at the time of RT using the NCCN thermometer and a 30 question survey of distress related items. PRD and clinical and demographic data was retrospectively collected and analyzed. The three measures this study focused on that assessed patient anxiety and depression involved asking patients about their level of concern regarding feeling down, regarding loss of interest, and regarding feeling nervous. Associations between baseline patient characteristics and survival after start of RT were evaluated using single variable Cox proportional hazards regression models. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. Associations of level of concern regarding patient anxiety/depression with survival after RT were evaluated using single variable and multivariable Cox proportional hazards regression models. Results: Overall, PRD level and concern regarding anxiety/depression were positively correlated (p < 0.001). Additionally, there was a significant association between level of concern regarding feeling down and palliative patients (p = 0.03). There was also a significant association between level of concern regarding loss of interest and palliative patients (p = 0.03), with level of concern highest for thorax, breast, and head and neck. There was also a significant different between level of concern regarding feeling nervous and gender (p = 0.05). There was not a significant difference between any of the three measures and survival after RT (all p ≥ 0.21). Conclusions: Anxiety and depression in patients receiving palliative and curative RT was associated with overall distress. Baseline screening of PRD may identify patients who would benefit from intervention to address the causes of their underlying anxiety and depression.
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Tran, Nhan L. , Halperin, Rebecca F. , Phillips, Joanna J. , Kuhn, John G. , Groot, John F. de, Colman, Howard , Wen, Patrick Y. , Mellinghoff, Ingo K. , Butowski, Nicholas , Taylor, Jennie , Clarke, Jennifer , Chang, Susan M. , Molinaro, Annette M. , Maggiora, Gerald M. , Peng, Sen, Liang, Winnie S. , Trent, Jeffrey M. , Berens, Michael E. , Carpten, John D. , Craig, David W. , Prados, Michael D. , Berens, Michael E , Byron, Sara A. , Colman, Howard , Ligon, Keith L , Wen, Patrick Yung , Cloughesy, Timothy F. , Chang, Susan Marina , Berger, Mitchel S. , Molinaro, Annette M. , Nasser, Sara A. , Mellinghoff, Ingo K , Tran, Nhan L

Mayo Clinic

Clinical Cancer Research | October 26, 2017 | Volume: 24 | Issue: 2 | Pages: 295-305

10.1158/1078-0432.ccr-17-0963 | PMID 29074604 Get It

Abstract Purpose: Glioblastoma is an aggressive and molecularly heterogeneous cancer with few effective treatment options. We hypothesized that next-generation sequencing can be used to guide treatment recommendations within a clinically acceptable time frame following surgery for patients with recurrent glioblastoma. Experimental Design: We conducted a prospective genomics-informed feasibility trial in adults with recurrent and progressive glioblastoma. Following surgical resection, genome-wide tumor/normal exome sequencing and tumor RNA sequencing were performed to identify molecular targets for potential matched therapy. A multidisciplinary molecular tumor board issued treatment recommendations based on the genomic results, blood–brain barrier penetration of the indicated therapies, drug–drug interactions, and drug safety profiles. Feasibility of generating genomics-informed treatment recommendations within 35 days of surgery was assessed. Results: Of the 20 patients enrolled in the study, 16 patients had sufficient tumor tissue for analysis. Exome sequencing was completed for all patients, and RNA sequencing was completed for 14 patients. Treatment recommendations were provided within the study's feasibility time frame for 15 of 16 (94%) patients. Seven patients received treatment based on the tumor board recommendations. Two patients reached 12-month progression-free survival, both adhering to treatments based on the molecular profiling results. One patient remained on treatment and progression free 21 months after surgery, 3 times longer than the patient's previous time to progression. Analysis of matched nonenhancing tissue from 12 patients revealed overlapping as well as novel putatively actionable genomic alterations. Conclusions: Use of genome-wide molecular profiling is feasible and can be informative for guiding real-time, central nervous system–penetrant, genomics-informed treatment recommendations for patients with recurrent glioblastoma. Clin Cancer Res; 24(2); 295–305. ©2017 AACR. See related commentary by Wick and Kessler, p. 256
Implant Density at the Apex Is More Important Than Overall Implant Density for 3D Correction in Thoracic Adolescent Idiopathic Scoliosis Using Rod Derotation and En Bloc Vertebral Derotation Technique
Delikaris, Alexandre, Wang, Xiaoyu , Boyer, Laure, Ledonio, Charles Gerald T., Aubin, Carl‐Éric , Larson, A. Noelle

Mayo Clinic

Spine | October 22, 2017 | Volume: 43 | Issue: 11 | Pages: E639-E647

10.1097/brs.0000000000002465 | PMID 29059123 Get It

Study Design. Biomechanical analysis of 3D correction and bone–screw forces through numerical simulations of scoliosis instrumentation with different pedicle screw patterns. Objective. To analyze the effect of different screw densities and distributions on 3D correction and bone–screw forces in adolescent idiopathic scoliosis (AIS) instrumentation. Summary of Background Data. Instrumentation constructs with various numbers of pedicle screws and patterns have been proposed for thoracic AIS instrumentation. However, systematic biomechanical studies have not yet been completed on the appropriate screw patterns for optimal 3D correction. Methods. Patient-specific biomechanical models of the spine were created for 10 AIS cases (Lenke 1). For each case, surgical instrumentation patterns were computationally simulated using respectively a reference screw pattern (two screws per level fused) and six alternative screw patterns with fewer screws. Simulated surgical maneuvers and model definition were unchanged between simulations except the number and distribution of screws. 3D correction and bone–screw forces were compared. Results. A total of 140 posterior instrumentations were computationally simulated. Mean corrections in the coronal and sagittal planes with alternative screw patterns were within 4° to the reference pattern. Increasing screw density in the apical region from one to two screws per level improved percent apical vertebral rotation (AVR) correction (r = 0.887, P < 0.05). Average bone–screw force associated with the reference screw pattern was 243N ± 54N and those with the alternative screw patterns were 11% to 48% lower. Conclusion. Compared with the reference maximal screw density pattern, alternative screw patterns allowed similar corrections in the coronal and sagittal planes. AVR correction was strongly correlated with screw density in the apical region; AVR correction varied significantly with screw patterns of the same overall screw density when an en bloc vertebral derotation technique was simulated. High screw density tended to overconstrain the instrumented spine and resulted in higher forces at the bone–screw interface. Level of Evidence: N/A
Test Assembly Implications for Providing Reliable and Valid Subscores
Lee, Minji K. , Sweeney, Kevin P, Melican, Gerald J.

Mayo Clinic

Educational Assessment | October 10, 2017 | Volume: 22 | Issue: 4 | Pages: 205-219

10.1080/10627197.2017.1381552 Get It

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial
Khorana, Alok A. , Vadhan‐Raj, Saroj , Kuderer, Nicole M. , Wun, Ted , Liebman, Howard A. , Soff, Gerald A. , O’Reilly, Eileen M. , McBane, Robert D. , Damaraju, C. V. , Beyers, Karen, Dietrich, Flavia, Kakkar, Ajay K. , Riess, Hanno, McBane, Robert , O'Reilly, Eileen M , Wun, Ted , Belani, Chandra P. , Eikelboom, John W. , Peixoto, Renata D’Alpino , Lyman, Gary H

Mayo Clinic

Thrombosis and Haemostasis | September 21, 2017 | Volume: 117 | Issue: 11 | Pages: 2135-2145

10.1160/th17-03-0171 | PMID 28933799 Get It

AbstractVenous thromboembolism (VTE) is a frequent complication of cancer associated with morbidity, mortality, increased hospitalizations and higher health care costs. Cancer patients at increased risk for VTE can be identified using a validated risk assessment score, and the incidence of VTE can be reduced in high-risk settings using anticoagulation. Rivaroxaban is a potent, oral, direct, factor Xa inhibitor approved for the prevention and treatment of thromboembolic events, including VTE. CASSINI is a double-blind, randomized, parallel-group, multicentre study comparing rivaroxaban with placebo in adult ambulatory patients with various cancers who are initiating systemic cancer therapy and are at high risk of VTE (Khorana score ≥ 2). Patients with primary brain tumours or those at risk for bleeding are excluded. Approximately 700 patients will be randomized 1:1 to rivaroxaban 10 mg daily or placebo for up to 6 months if there is no evidence of VTE from compression ultrasonography (CU) during screening or from routine care imaging within 30 days prior to randomization. Mandatory CU will also be performed at weeks 8 and 16 (±7 days), and at study end (±3 days). The primary efficacy hypothesis is that anticoagulation with rivaroxaban reduces the composite of objectively confirmed symptomatic or asymptomatic, lower-extremity, proximal deep-vein thrombosis (DVT); symptomatic, upper-extremity DVT; symptomatic or incidental pulmonary embolism; and VTE-related death compared with placebo. The primary safety objective is to assess major bleeding events (Clinical trial information: NCT02555878).
Allelic spectrum of formiminotransferase‐cyclodeaminase gene variants in individuals with formiminoglutamic aciduria
Majumdar, Ramanath, Yori, Andrew, Rush, Peggy W., Raymond, Kimiyo , Gavrilov, Dimitar , Tortorelli, Silvia , Matern, Dietrich , Rinaldo, Piero, Feldman, Gerald L. , Oglesbee, Devin , Oglesbee, Devin

Mayo Clinic

Molecular Genetics & Genomic Medicine | September 12, 2017 | Volume: 5 | Issue: 6 | Pages: 795-799

10.1002/mgg3.333 | PMID 29178637 Get It

AbstractBackgroundElevated plasma and urine formiminoglutamic acid (FIGLU) levels are commonly indicative of formiminoglutamic aciduria (OMIM #229100), a poorly understood autosomal recessive disorder of histidine and folate metabolism, resulting from formiminotransferase‐cyclodeaminase (FTCD) deficiency, a bifunctional enzyme encoded by FTCD.MethodsIn order to further understanding about the molecular alterations that contribute to FIGLU‐uria, we sequenced FTCD in 20 individuals with putative FTCD deficiency and varying laboratory findings, including increased FIGLU excretion.ResultsIndividuals tested had biallelic loss‐of‐function variants in protein‐coding regions of FTCD. The FTCD allelic spectrum comprised of 12 distinct variants including 5 missense alterations that replace conserved amino acid residues (c.223A>C, c.266A>G, c.319T>C, c.430G>A, c.514G>T), an in‐frame deletion (c.1373_1375delTGG), with the remaining alterations predicted to affect mRNA processing/stability. These included two frameshift variants (c.990dup, c.1366dup) and four nonsense variants (c.337C>T, c.451A>T, c.763C>T, c.1607T>A).ConclusionWe observed additional FTCD alleles leading to urinary FIGLU elevations, and thus, providing molecular evidence of FTCD deficiency in cases identified by newborn screening or clinical biochemical genetic laboratory testing.